DOCSLIB.ORG

Biased Receptor Functionality Versus Biased Agonism in G-Protein-Coupled Receptors Journal Xyz 2017; 1 (2): 122–135

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biased Receptor Functionality Versus Biased Agonism in G-Protein-Coupled Receptors Journal Xyz 2017; 1 (2): 122–135 BioMol Concepts 2018; 9: 143–154 Review Open Access Rafael Franco*, David Aguinaga, Jasmina Jiménez, Jaume Lillo, Eva Martínez-Pinilla*#, Gemma Navarro# Biased receptor functionality versus biased agonism in G-protein-coupled receptors Journal xyz 2017; 1 (2): 122–135 https://doi.org/10.1515/bmc-2018-0013 b-arrestins or calcium sensors are also provided. Each of receivedThe FirstJuly 19, Decade 2018; accepted (1964-1972) November 2, 2018. the functional GPCR units (which are finite in number) has Abstract:Research Functional Article selectivity is a property of G-protein- a specific conformation. Binding of agonist to a specific coupled receptors (GPCRs) by which activation by conformation, i.e. GPCR activation, is sensitive to the differentMax Musterman, agonists leads Paul to differentPlaceholder signal transduction kinetics of the agonist-receptor interactions. All these mechanisms. This phenomenon is also known as biased players are involved in the contrasting outputs obtained agonismWhat and Is has So attracted Different the interest Aboutof drug discovery when different agonists are assayed. programsNeuroenhancement? in both academy and industry. This relatively recent concept has raised concerns as to the validity and Keywords: conformational landscape; GPCR heteromer; realWas translational ist so value anders of the results am showing Neuroenhancement? bias; firstly cytocrin; effectors; dimer; oligomer; structure. biased agonism may vary significantly depending on the cellPharmacological type and the experimental and Mental constraints, Self-transformation secondly the in Ethic conformationalComparison landscape that leads to biased agonism Introduction hasPharmakologische not been defined. Remarkably,und mentale GPCRs Selbstveränderung may lead to im differential signaling even when a single agonist is used. Functional selectivity is triggered by binding of agonists ethischen Vergleich Here we present a concept that constitutes a biochemical interacting with residues at the orthosteric binding site that property of GPCRs that may be underscored just using results in a conformational change in regions that are close https://doi.org/10.1515/xyz-2017-0010 one agonist, preferably the endogenous agonist. “Biased to the intracellular domains. In silico modeling suggests received February 9, 2013; accepted March 25, 2013; published online July 12, 2014 receptor functionality” is proposed to describe this that the second intracellular loop of the serotonin 5-HT2A effectAbstract: with Inexamples the concept based of theon receptor aesthetic heteromerization formation of knowledge receptor and is involvedits as soon in functional selectivity. The binding andas alternativepossible and splicing. success-oriented Examples ofapplication, regulation insights of final and of profitsdifferent without agonists the results in different conformations of agonist-inducedreference to the outputsarguments based developed on interactionaround 1900. with The mainthe intracelularinvestigation loops, also ultimately resulting in contrasting includes the period between the entry into force and the presentationfunctional in itsoutputs current (1). Residues in transmembrane version. Their function as part of the literary portrayal and domainnarrative 3 technique.are also proposed to be important for functional selectivity in muscarinic (2), cannabinoid (3) and β - *CorrespondingKeywords: Function, author: Rafael transmission, Franco, Molecular investigation, Neurobiology principal, period 2 laboratory. Department of Biochemistry and Molecular adrenergic (4) receptors. Similarly, other regions within Biomedicine, Biology School, University of Barcelona, Spain; the G-protein-coupled receptor (GPCR) structure may Dedicated to Paul Placeholder Centro de Investigación en Red, Enfermedades Neurodegenerativas participate specifically in activating a given signaling (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain, E-mail: pathway. This mini-review focuses on the biased receptor [email protected]; Eva Martínez-Pinilla, Departamento de Morfología functionality, a phenomenon that may be underscored by y Biología Celular, Facultad de Medicina, Universidad de Oviedo, Asturias,1 Studies Spain; Instituto and de NeurocienciasInvestigations del Principado de a single agonist leading to different signaling outputs in Asturias (INEUROPA), Asturias, Spain; Instituto de Salud del different cells or even in the same cell. This phenomenon PrincipadoThe main de investigationAsturias (ISPA), alsoAsturias, includes Spain the period between theseemingly entry into involves force and similar mechanisms to those leading Davidthe Aguinaga,presentation Jaume in Lillo: its currentMolecular version. Neurobiology Their laboratory. function as partto biased of the agonismliterary por and- to what is known as “system bias” Department of Biochemistry and Molecular Biomedicine, Biology trayal and narrative technique. (5–7), a concept whose definition and usefulness await School, University of Barcelona, Spain David Aguinaga, Jasmina Jiménez, Gemma Navarro: Centro general consensus. de Investigación en Red, Enfermedades Neurodegenerativas (CIBERNED),*Max Musterman: Instituto Institute de Salud of Carlos Marine III, Biology, Madrid, National Spain Taiwan Ocean University, 2 Pei-Ning GemmaRoad Keelung Navarro: 20224, Department Taiwan of (R.O.C), Biochemistry e-mail: and [email protected] Physiology, PharmacyPaul Placeholder: and Food ScienceInstitute School, of Marine University Biology, of National Barcelona, Taiwan Spain Ocean University, 2 Pei-Ning #EqualRoad contribution Keelung 20224, Taiwan (R.O.C), e-mail: [email protected] Journal xyz 2017; 1 (2): 122–135 Open Open Access.Access. © © 2017 2018 Mustermann Rafael Franco and Placeholder, et al., published published by by De De Gruyter. Gruyter. ThisThis work work is is licensed under the Creative Commons Attribution-NonCommercial-NoDerivativeslicensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License. 4.0 License. The First Decade (1964-1972) Research Article Max Musterman, Paul Placeholder What Is So Different About Neuroenhancement? Was ist so anders am Neuroenhancement? Pharmacological and Mental Self-transformation in Ethic Comparison Pharmakologische und mentale Selbstveränderung im ethischen Vergleich https://doi.org/10.1515/xyz-2017-0010 received February 9, 2013; accepted March 25, 2013; published online July 12, 2014 Abstract: In the concept of the aesthetic formation of knowledge and its as soon as possible and success-oriented application, insights and profits without the reference to the arguments developed around 1900. The main investigation also includes the period between the entry into force and the presentation in its current version. Their function as part of the literary portrayal and narrative technique. Keywords: Function, transmission, investigation, principal, period Dedicated to Paul Placeholder 1 Studies and Investigations The main investigation also includes the period between the entry into force and the presentation in its current version. Their function as part of the literary por- trayal and narrative technique. *Max Musterman: Institute of Marine Biology, National Taiwan Ocean University, 2 Pei-Ning Road Keelung 20224, Taiwan (R.O.C), e-mail: [email protected] Paul Placeholder: Institute of Marine Biology, National Taiwan Ocean University, 2 Pei-Ning Road Keelung 20224, Taiwan (R.O.C), e-mail: [email protected] Open Access. © 2017 Mustermann and Placeholder, published by De Gruyter. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License. 144 R. Franco et al: Biased GPCR functionality and biased agonism Figure 1: A scheme on functional selectivity based on differential agonist bias. Taken from (13)(fig. 2), with permission. Functional selectivity or biased quantitative aspects of biased agonism appeared later. The agonism: historical perspective effects of different adrenoceptor agonists on two signaling responses, namely regulation of cAMP levels and MAPK “Functional selectivity” and “biased agonism” can be pathway activation, were determined, and the results were used interchangeably and can be considered synonymous summarized as “the results suggest that binding of different to one another. (1,8,9). The following sentence highlights ligands promote distinct conformational changes leading GPCR conformational states as the reason for biased to specific signaling outcomes. Our data therefore clearly agonism: “Different conformations adopted by receptors illustrate that efficacy is a pluridimensional parameter after associating with specific ligands can determine that is not an intrinsic characteristic of a ligand/receptor which intracellular signaling pathways get activated couple” (15). Since then the idea of biased agonism, which and which do not”; this sentence appears in the article is related to therapeutic benefits of functional selectivity, entitled “Functional selectivity, ligand-directed trafficking, has gained momentum both in academia and in drug conformation-specific agonism: What’s in a name” (10). discovery programs in the Pharmaceutical industry The link between biased agonism and stabilization (Figure 1). Current drug discovery programs consider of different receptor conformations leading to diverse GPCR biased agonism and have developed strategies to signaling pathways is also reported in complementary select the most effective biased compound. reviews (11,12). Biased agonism was first “measured” by ranking the
Load more

Recommended publications
  • Understanding the Role of GPCR Heteroreceptor Complexes in Modulating the Brain Networks in Health and Disease
    REVIEW published: 21 February 2017 doi: 10.3389/fncel.2017.00037 Understanding the Role of GPCR Heteroreceptor Complexes in Modulating the Brain Networks in Health and Disease Dasiel O. Borroto-Escuela 1,2,3, Jens Carlsson 4, Patricia Ambrogini 2, Manuel Narváez 5, Karolina Wydra 6, Alexander O. Tarakanov 7, Xiang Li 1, Carmelo Millón 5, Luca Ferraro 8, Riccardo Cuppini 2, Sergio Tanganelli 9, Fang Liu 10, Malgorzata Filip 6, Zaida Diaz-Cabiale 5 and Kjell Fuxe 1* 1Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden, 2Department of Biomolecular Science, Section of Physiology, University of Urbino, Urbino, Italy, 3Observatorio Cubano de Neurociencias, Grupo Bohío-Estudio, Yaguajay, Cuba, 4Department of Cell and Molecular Biology, Uppsala Biomedical Centre (BMC), Uppsala University, Uppsala, Sweden, 5Facultad de Medicina, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, Málaga, Spain, 6Laboratory of Drug Addiction Pharmacology, Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland, 7St. Petersburg Institute for Informatics and Automation, Russian Academy of Sciences, Saint Petersburg, Russia, 8Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy, 9Department of Medical Sciences, University of Ferrara, Ferrara, Italy, 10Campbell Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada The introduction of allosteric receptor–receptor interactions in G protein-coupled receptor (GPCR) heteroreceptor complexes of the central nervous system (CNS) gave a new dimension to brain integration and neuropsychopharmacology. The molecular basis Edited by: Hansen Wang, of learning and memory was proposed to be based on the reorganization of the homo- University of Toronto, Canada and heteroreceptor complexes in the postjunctional membrane of synapses.
    [Show full text]
  • Principle of Pharmacodynamics
    Principle of pharmacodynamics Dr. M. Emamghoreishi Full Professor Department of Pharmacology Medical School Shiraz University of Medical Sciences Email:[email protected] Reference: Basic & Clinical Pharmacology: Bertrum G. Katzung and Anthony J. Treveror, 13th edition, 2015, chapter 20, p. 336-351 Learning Objectives: At the end of sessions, students should be able to: 1. Define pharmacology and explain its importance for a clinician. 2. Define ―drug receptor‖. 3. Explain the nature of drug receptors. 4. Describe other sites of drug actions. 5. Explain the drug-receptor interaction. 6. Define the terms ―affinity‖, ―intrinsic activity‖ and ―Kd‖. 7. Explain the terms ―agonist‖ and ―antagonist‖ and their different types. 8. Explain chemical and physiological antagonists. 9. Explain the differences in drug responsiveness. 10. Explain tolerance, tachyphylaxis, and overshoot. 11. Define different dose-response curves. 12. Explain the information that can be obtained from a graded dose-response curve. 13. Describe the potency and efficacy of drugs. 14. Explain shift of dose-response curves in the presence of competitive and irreversible antagonists and its importance in clinical application of antagonists. 15. Explain the information that can be obtained from a quantal dose-response curve. 16. Define the terms ED50, TD50, LD50, therapeutic index and certain safety factor. What is Pharmacology?It is defined as the study of drugs (substances used to prevent, diagnose, and treat disease). Pharmacology is the science that deals with the interactions betweena drug and the bodyor living systems. The interactions between a drug and the body are conveniently divided into two classes. The actions of the drug on the body are termed pharmacodynamicprocesses.These properties determine the group in which the drug is classified, and they play the major role in deciding whether that group is appropriate therapy for a particular symptom or disease.
    [Show full text]
  • Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity Kelly A
    International Journal of Neuropsychopharmacology (2018) 21(10): 962–977 doi:10.1093/ijnp/pyy071 Advance Access Publication: August 6, 2018 Review review Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity Kelly A. Berg and William P. Clarke Department of Pharmacology, University of Texas Health, San Antonio, Texas. Correspondence: William P. Clarke, PhD, Department of Pharmacology, Mail Stop 7764, UT Health at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229 ([email protected]). Abstract Constitutive receptor activity/inverse agonism and functional selectivity/biased agonism are 2 concepts in contemporary pharmacology that have major implications for the use of drugs in medicine and research as well as for the processes of new drug development. Traditional receptor theory postulated that receptors in a population are quiescent unless activated by a ligand. Within this framework ligands could act as agonists with various degrees of intrinsic efficacy, or as antagonists with zero intrinsic efficacy. We now know that receptors can be active without an activating ligand and thus display “constitutive” activity. As a result, a new class of ligand was discovered that can reduce the constitutive activity of a receptor. These ligands produce the opposite effect of an agonist and are called inverse agonists. The second topic discussed is functional selectivity, also commonly referred to as biased agonism. Traditional receptor theory also posited that intrinsic efficacy is a single drug property independent of the system in which the drug acts. However, we now know that a drug, acting at a single receptor subtype, can have multiple intrinsic efficacies that differ depending on which of the multiple responses coupled to a receptor is measured.
    [Show full text]
  • Biopharmacy Practice
    University of Szeged Biopharmacy practice Editor: Árpád Márki, Ph.D. Authors: Árpád Márki, Ph.D. Adrienn Seres, Ph.D. Anita Sztojkov-Ivanov, Ph.D. Reviewed by: Szilárd Pál, Ph.D. Szeged, 2015. This work is supported by the European Union, co-financed by the European Social Fund, within the framework of "Coordinated, practice-oriented, student-friendly modernization of biomedical education in three Hungarian universities (Pécs, Debrecen, Szeged), with focus on the strengthening of international competitiveness" TÁMOP-4.1.1.C-13/1/KONV-2014-0001 project. The curriculum cannot be sold in any form! Contents Contents ...................................................................................................................................... 2 1. Definitions, routes of drug administration ............................................................................. 6 1.1. Definitions ....................................................................................................................... 6 1.2. Routes of drug administration ......................................................................................... 7 1.3. Questions ....................................................................................................................... 10 2. Receptors .............................................................................................................................. 11 2.1. Definitions ....................................................................................................................
    [Show full text]
  • When Simple Agonism Is Not Enough: Emerging Modalities of GPCR Ligands Nicola J
    When simple agonism is not enough: emerging modalities of GPCR ligands Nicola J. Smith, Kirstie A. Bennett, Graeme Milligan To cite this version: Nicola J. Smith, Kirstie A. Bennett, Graeme Milligan. When simple agonism is not enough: emerging modalities of GPCR ligands. Molecular and Cellular Endocrinology, Elsevier, 2010, 331 (2), pp.241. 10.1016/j.mce.2010.07.009. hal-00654484 HAL Id: hal-00654484 https://hal.archives-ouvertes.fr/hal-00654484 Submitted on 22 Dec 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Accepted Manuscript Title: When simple agonism is not enough: emerging modalities of GPCR ligands Authors: Nicola J. Smith, Kirstie A. Bennett, Graeme Milligan PII: S0303-7207(10)00370-9 DOI: doi:10.1016/j.mce.2010.07.009 Reference: MCE 7596 To appear in: Molecular and Cellular Endocrinology Received date: 15-1-2010 Revised date: 15-6-2010 Accepted date: 13-7-2010 Please cite this article as: Smith, N.J., Bennett, K.A., Milligan, G., When simple agonism is not enough: emerging modalities of GPCR ligands, Molecular and Cellular Endocrinology (2010), doi:10.1016/j.mce.2010.07.009 This is a PDF file of an unedited manuscript that has been accepted for publication.
    [Show full text]
  • Regulation of Ion Channels by Muscarinic Receptors
    Regulation of ion channels by muscarinic receptors David A. Brown Department of Neuroscience, Physiology & Pharmacology, University College London, London, WC1E 6BT (UK). Contact address: Professor D.A.Brown, FRS, Department of Neuroscience, Physiology & Pharmacology, University College London, Gower Street, Londin, WC1E 6BT. E-mail: [email protected] Telephone: (+44) (0)20 7679 7297 Mobile (for urgent messages): (+44)(0)7766-236330 Abstract The excitable behaviour of neurons is determined by the activity of their endogenous membrane ion channels. Since muscarinic receptors are not themselves ion channels, the acute effects of muscarinic receptor stimulation on neuronal function are governed by the effects of the receptors on these endogenous neuronal ion channels. This review considers some principles and factors determining the interaction between subtypes and classes of muscarinic receptors with neuronal ion channels, and summarizes the effects of muscarinic receptor stimulation on a number of different channels, the mechanisms of receptor – channel transduction and their direct consequences for neuronal activity. Ion channels considered include potassium channels (voltage-gated, inward rectifier and calcium activated), voltage-gated calcium channels, cation channels and chloride channels. Key words: Ion channels; neuronal excitation and inhibition; pre- and postsynaptic events; muscarinic receptor subtypes; G proteins; transduction mechanisms. Contents. 1. Introduction: some principles of muscarinic receptor – ion channel coupling. 1.2 Some consequences of the indirect link between receptor and ion channel. + The connection between M1Rs and the M-type K channel as a model system 1.2.1 Dynamics of the response 1.2.2 Sensitivity of the response to agonist stimulation 2. Some muscarinic receptor-modulated neural ion channels.
    [Show full text]
  • Monoaminergic Neuromodulation of Sensory Processing
    fncir-12-00051 July 6, 2018 Time: 17:34 # 1 REVIEW published: 10 July 2018 doi: 10.3389/fncir.2018.00051 Monoaminergic Neuromodulation of Sensory Processing Simon N. Jacob1* and Hendrikje Nienborg2* 1 Department of Neurosurgery, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany, 2 Werner Reichardt Centre for Integrative Neuroscience, University of Tübingen, Tübingen, Germany All neuronal circuits are subject to neuromodulation. Modulatory effects on neuronal processing and resulting behavioral changes are most commonly reported for higher order cognitive brain functions. Comparatively little is known about how neuromodulators shape processing in sensory brain areas that provide the signals for downstream regions to operate on. In this article, we review the current knowledge about how the monoamine neuromodulators serotonin, dopamine and noradrenaline influence the representation of sensory stimuli in the mammalian sensory system. We review the functional organization of the monoaminergic brainstem neuromodulatory systems in relation to their role for sensory processing and summarize recent neurophysiological evidence showing that monoamines have diverse effects on early sensory processing, including changes in gain and in the precision of neuronal responses to sensory inputs. We also highlight the substantial evidence for complementarity between these neuromodulatory systems with different patterns of Edited by: innervation across brain areas and cortical layers as well as distinct neuromodulatory Anita Disney, actions. Studying the effects of neuromodulators at various target sites is a crucial step Vanderbilt University, United States in the development of a mechanistic understanding of neuronal information processing Reviewed by: Summer Sheremata, in the healthy brain and in the generation and maintenance of mental diseases.
    [Show full text]
  • Drug Action-Receptor Theory
    Drug action-Receptor Theory Molecules (eg, drugs, hormones, neurotransmitters) that bind to a receptor are called ligands. The binding can be specific and reversible. A ligand may activate or inactivate a receptor; activation may increase or decrease a particular cell function. Each ligand may interact with multiple receptor subtypes. Few if any drugs are absolutely specific for one receptor or subtype, but most have relative selectivity. Selectivity is the degree to which a drug acts on a given site relative to other sites; selectivity relates largely to physicochemical binding of the drug to cellular receptors. A drug’s ability to affect a given receptor is related to the drug’s affinity (probability of the drug occupying a receptor at any given instant) and intrinsic efficacy (intrinsic activity—degree to which a ligand activates receptors and leads to cellular response). A drug’s affinity and activity are determined by its chemical structure. The pharmacologic effect is also determined by the duration of time that the drug-receptor complex persists (residence time). The lifetime of the drug-receptor complex is affected by dynamic processes (conformation changes) that control the rate of drug association and dissociation from the target. A longer residence time explains a prolonged pharmacologic effect. Drugs with long residence times include finasteride and darunavir. A longer residence time can be a potential disadvantage when it prolongs a drug's toxicity. For some receptors, transient drug occupancy produces the desired pharmacologic effect, whereas prolonged occupancy causes toxicity. Ability to bind to a receptor is influenced by external factors as well as by intracellular regulatory mechanisms.
    [Show full text]
  • Anatomy and Physiology of Me- Tabotropic Glutamate Receptors in Mammalian and Avian Audi- Tory System
    Zheng-Quan Tang and Lu Y, Trends Anat Physiol 2018, 1: 001 DOI: 10.24966/TAP-7752/100001 HSOA Trends in Anatomy and Physiology Review Article Abbreviations Anatomy and Physiology of Me- AC: Auditory Cortex tabotropic Glutamate Receptors AVCN: Anteroventral Cochlear Nucleus CN: Cochlear Nucleus in Mammalian and Avian Audi- DCN: Dorsal Cochlear Nucleus EPSC/P: Excitatory Postsynaptic Current/Potential GABA R: GABA Receptor tory System B B + Zheng-Quan Tang1 and Yong Lu2* GIRK: G-Protein- Coupled Inward Rectifier K HF: High-Frequency 1Oregon Hearing Research Center, Vollum Institute, Oregon Health and IC: Inferior Colliculus Science University, Oregon, USA IGluR: Ionotropic Glutamate Receptor 2Department of Anatomy and Neurobiology, Northeast Ohio Medical IHC: Inner Hair Cell University, Ohio, USA IPSC/P: Inhibitory Postsynaptic Current/Potential LF: Low Frequency LSO: Lateral Superior Live LTD/P: Long-Term Depression/Potentiation MF: Middle-Frequency MGB: Medial Geniculate Body mGluR: Metabotropic Glutamate Receptor MNTB: Medial Nucleus of Trapezoid Body MSO: Medial Superior Olive Abstract mRNA: Messenger Ribonucleic Acid Glutamate, as the major excitatory neurotransmitter used in the NA: Nucleus Angularis vertebrate brain, activates ionotropic and metabotropic glutamate NL: Nucleus Laminaris receptors (iGluRs and mGluRs), which mediate fast and slow neu- NM: Nucleus Magnocellularis ronal actions, respectively. mGluRs play important modulatory roles OHC: Outer Hair Cell in many brain areas, forming potential targets for drugs developed PVCN: Posteroventral Cochlear Nucleus to treat brain disorders. Here, we review studies on mGluRs in the mammalian and avian auditory system. Although anatomical expres- SON: Superior Olivary Nucleus sion of mGluRs in the cochlear nucleus has been well character- VCN: Ventral Cochlear Nucleus ized, data for other auditory nuclei await more systematic investi- VGCC: Voltage-Gated Ca2+ Channel gations especially at the electron microscopy level.
    [Show full text]
  • International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification
    0031-6997/03/5504-597–606$7.00 PHARMACOLOGICAL REVIEWS Vol. 55, No. 4 Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics 30404/1114803 Pharmacol Rev 55:597–606, 2003 Printed in U.S.A International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology RICHARD R. NEUBIG, MICHAEL SPEDDING, TERRY KENAKIN, AND ARTHUR CHRISTOPOULOS Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.); Institute de Recherches Internationales Servier, Neuilly sur Seine, France (M.S.); Systems Research, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina (T.K.); and Department of Pharmacology, University of Melbourne, Parkville, Australia (A.C.) Abstract ............................................................................... 597 I. Introduction............................................................................ 597 II. Working definition of a receptor .......................................................... 598 III. Use of drugs in definition of receptors or of signaling pathways ............................. 598 A. The expression of amount of drug: concentration and dose ............................... 598 1. Concentration..................................................................... 598 2. Dose. ............................................................................ 598 B. General terms used to describe drug action ...........................................
    [Show full text]
  • P2Y6R Agonist
    Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. P2Y6R Agonist Evidence Summary P2Y6R activation promotes microglial phagocytosis, but also drives vascular inflammation, so agonists may exacerbate cardiovascular disease. Short term safety is good, but long-term safety is unknown. Neuroprotective Benefit: P2Y6R stimulation promotes microglial activation and phagocytosis which may facilitate amyloid clearance, but may also promote neuroinflammation and neuronal loss. Aging and related health concerns: P2Y6R activity is associated with the exacerbation of hypertension, atherosclerosis, neuropathic pain, and cancer metastasis in preclinical models, but may benefit glaucoma. Safety: The agonist GC021109 was safe in short Phase 1 trials, but long-term safety has not been established. Effects may vary in different patient populations. 1 Availability: Research use Dose: Not established Endogenous agonist: UDP Chemical formula: C9H14N2O12P2 Half-life: Not reported BBB: Not reported MW: 404.16 g/mol Clinical trials: Two Phase 1 studies for Observational studies: GC021109 in healthy controls (n=44) None and mild/moderate AD (n=36). Source: PubChem What is it? The P2Y6 receptor (P2Y6R) is a G-protein coupled receptor (GPCR) which belongs to the class of purinergic receptors.
    [Show full text]
  • Pharmacology of Free Fatty Acid Receptors and Their Allosteric Modulators
    International Journal of Molecular Sciences Review Pharmacology of Free Fatty Acid Receptors and Their Allosteric Modulators Manuel Grundmann 1,* , Eckhard Bender 2, Jens Schamberger 2 and Frank Eitner 1 1 Research and Early Development, Bayer Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany; [email protected] 2 Drug Discovery Sciences, Bayer Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany; [email protected] (E.B.); [email protected] (J.S.) * Correspondence: [email protected] Abstract: The physiological function of free fatty acids (FFAs) has long been regarded as indirect in terms of their activities as educts and products in metabolic pathways. The observation that FFAs can also act as signaling molecules at FFA receptors (FFARs), a family of G protein-coupled receptors (GPCRs), has changed the understanding of the interplay of metabolites and host responses. Free fatty acids of different chain lengths and saturation statuses activate FFARs as endogenous agonists via binding at the orthosteric receptor site. After FFAR deorphanization, researchers from the pharmaceutical industry as well as academia have identified several ligands targeting allosteric sites of FFARs with the aim of developing drugs to treat various diseases such as metabolic, (auto)inflammatory, infectious, endocrinological, cardiovascular, and renal disorders. GPCRs are the largest group of transmembrane proteins and constitute the most successful drug targets in medical history. To leverage the rich biology of this target class, the drug industry seeks alternative approaches to address GPCR signaling. Allosteric GPCR ligands are recognized as attractive modalities because Citation: Grundmann, M.; Bender, of their auspicious pharmacological profiles compared to orthosteric ligands. While the majority of E.; Schamberger, J.; Eitner, F.
    [Show full text]